23 results about "Coliphage" patented technology

The invention belongs to the field of poultry infectious diseases, and particularly relates to a riemerella anatipestifer phage mutant strain and a method for quickly mutating riemerella anatipestifer phage. Escherichia coli bacteriophage, riemerella anatipestifer bacteriophage and corresponding host bacteria are mixed, the infection complex number is made to be larger than 100, after culture, supernate is taken and then mixed with the host bacteria for culture, a bacteriophage mutant strain is separated from a secondary culture solution, the phage spectrum of the bacteriophage mutant strain is detected, and the mutant strain with the broadened phage spectrum is screened. At present, no report for widening the bacteriophage spectrum of the riemerella anatipestifer based on similar principles is found, and the research can fill the blank in the related research field.

The invention belongs to the technical field of microorganisms, and discloses a phage capable of efficiently splitting escherichia coli and salmonella, a preparation and application of the phage, the name is SP1, the classification name is escherichia coli phage, the preservation number is CGMCC No.46440, the preservation date is China General Microbiological Culture Collection Center on May 30, 2025, and the preservation unit is China General Microbiological Culture Collection Center. The optimal infection complex number of the bacteriophage is 1, the bacteriophage has very strong acid resistance and thermal stability, and the bacteriophage can keep high titer under the conditions that the pH value is 4-11, the temperature is 10-70 DEG C and the ultraviolet irradiation is within 30 minutes. The incubation period of escherichia coli infected by the bacteriophage is about 30 min, the outbreak period is about 40 min after the incubation period, and the bacteriophage can specifically split escherichia coli and salmonella, does not contain virulence and drug-resistant genes and is high in biological safety.

The invention relates to the technical field of microorganisms, in particular to an escherichia coli bacteriophage for improving the antibacterial effect of cecropin and application of the escherichia coli bacteriophage. The bacteriophage is named as RDP-EC-22139, the genome of the bacteriophage does not contain virulence genes and lyogenicity related genes, and the bacteriophage has good biological safety. The bacteriophage has relatively strong lysis activity on drug-resistant pathogenic escherichia coli, can still keep stable lysis titer in a relatively wide temperature and pH condition range, and has good genetic stability. When the bacteriophage is combined with cecropin for use, the minimum inhibitory concentration of the cecropin on drug-resistant pathogenic escherichia coli is remarkably reduced, the minimum inhibitory concentration can be reduced to 1 / 2-1 / 8 of the minimum inhibitory concentration when the cecropin is independently used, the inhibition time on pathogenic bacteria is remarkably prolonged, and a stable and unexpected synergistic antibacterial effect is shown. The invention provides a safe and effective biological technical scheme for prevention and control of drug-resistant Escherichia coli infection, and has a good application prospect.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The invention discloses an Escherichia coli bacteriophage D9, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D9 is CGMCC (China General Microbiological Culture Collection Center) NO. 46365, and the Escherichia coli bacteriophage D9 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D9 and other bacteriophages. The coliphage D9 has better high-temperature resistance and acid resistance, is high in breeding speed, is suitable for industrial production, has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a pharmaceutical preparation or a disinfectant, and has a wide application prospect. The compound is applied to the aspects of sterilization, bacteriostasis and disinfection of multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by escherichia coli and the like.

The invention discloses an Escherichia coli bacteriophage D5, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage D5 is CGMCC (China General Microbiological Culture Collection Center) NO. 46364, and the Escherichia coli bacteriophage D5 is preserved in China General Microbiological Culture Collection Center on January 2, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises an escherichia coli bacteriophage D5 and other bacteriophages. The Escherichia coli phage D5 has good high temperature resistance and acid resistance, the environmental tolerance enables the Escherichia coli phage D5 to keep high activity and stability and high breeding speed in industrial production, and the Escherichia coli phage D5 is suitable for industrial production and supports rapid proliferation and large-scale fermentation production requirements; the compound has excellent splitting performance on multiple strains of multi-drug-resistant clinical escherichia coli, can be used as an active ingredient of a biological bactericide, a medicinal preparation or a disinfectant, and is applied to the aspects of sterilization, bacteriostasis and disinfection of the multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by the escherichia coli and the like.

The application discloses an Aeromonas phage recombinant system, an expression vector, a recombinant strain and application thereof, and the recombinant system comprises a recombinase operon 109TES derived from a salmonella Aeromonas phage vB_AsaM-56; the operon comprises at least one gene with exonuclease function and one single-stranded DNA annealing protein gene. Through function verification in Escherichia coli, 109TES can efficiently mediate linear circle recombination and linear linear recombination by using a short homologous arm (50 bp), and has stable and reliable recombination function in a heterologous host, indicating that the recombinase operon from a non-Escherichia coli phage can also exert efficient homologous recombination function in Escherichia coli, and can be used as a powerful candidate for constructing a new type of recombination tool, and provides a new choice for developing a multi-host available gene editing system.

The invention relates to the technical field of preparation of biological agents, and particularly discloses a method for improving the stability and antibacterial persistence of an Escherichia coli bacteriophage preparation. The method comprises the following steps: adding chitosan in a culture process of escherichia coli host bacteria, and inoculating bacteriophage to complete lysis proliferation when the host bacteria are in a logarithmic phase; sequentially carrying out low-shear-force centrifugation, membrane filtration and membrane concentration treatment on the obtained bacteriophage proliferation liquid; adding a compound stabilizer consisting of EDTA (Ethylene Diamine Tetraacetic Acid), glycine, glycerol, trehalose and polyethylene glycol into the concentrated bacteriophage solution for stabilizing treatment; and finally, carrying out multi-stage filtration sterilization to obtain the phage preparation. The coliphage preparation prepared by the method shows good titer retention performance under normal-temperature and low-temperature storage conditions, and has longer effective antibacterial duration. The method is mild in preparation process, high in repeatability and suitable for large-scale preparation.

The purpose is to provide a novel bacteriophage having a wider range of bacterial strains that serve as hosts for infection than conventional bacteriophages and having bacteriolytic activity against Escherichia coli, including drug-resistant E. coli. The present inventors have discovered a novel bacteriophage having a broad antibacterial spectrum against E. coli, including drug-resistant E. coli. The phage was named ΦWec 277 phage and deposited with the Patent Microorganism Depositary (NPMD) of the National Institute of Technology and Evaluation (NITE) (accession number: NITE P-04067). It was discovered that E. coli can be effectively eliminated by using this bacteriophage, and the present invention was completed. Furthermore, genomic analysis of the ΦWec 277 phage was performed to clarify the full-length sequence. This ΦWec 277 phage was identified as a bacteriophage belonging to the Caudoviricetes Straboviridae as a result of phylogenetic analysis.

The invention relates to the technical field of biology, in particular to phage receptor binding protein D911 and application thereof. The invention provides preparation of an Escherichia coli phage receptor binding protein D911 and application of the Escherichia coli phage receptor binding protein D911 in detection of escherichia coli. The bacteriophage receptor binding protein D911 can specifically recognize and bind escherichia coli, the protein is further coupled with magnetic nanoparticles to form an escherichia coli receptor binding protein-magnetic bead conjugate D911-MNP, and a biological probe for specifically recognizing and binding escherichia coli is prepared and serves as an escherichia coli specific capture reagent. And a constructed escherichia coli separation and detection method. The method has the advantages of rapidness, convenience, specificity, sensitivity and accuracy, is expected to be applied to rapid detection of escherichia coli, and provides powerful technical support for escherichia coli detection in the fields of clinical diagnosis, food safety, environment and the like.

The invention discloses an aeromonas bacteriophage recombination system, an expression vector, a recombination strain and application of the aeromonas bacteriophage recombination system. The recombination system comprises a recombinase operon 109TES derived from aeromonas salmonicida bacteriophage vBAsaM-56; the operon comprises at least one gene with exonuclease function and a single-stranded DNA annealing protein gene. Through functional verification in Escherichia coli, 109TES can utilize a short homologous arm (50bp) to efficiently mediate wire loop recombination and wire-line recombination, and has a stable and dependable recombination function in a heterologous host, which indicates that a recombinase operon from a non-Escherichia coli bacteriophage can also exert an efficient homologous recombination function in the Escherichia coli, so that the recombinant enzyme operon can be used for preparing a recombinant vector. The method can be used as a powerful candidate for constructing a novel recombination tool, and a new choice is provided for developing a multi-host available gene editing system.

The present application relates to a pathogen-like antigen (PLA) complex, and a preparation method therefor and an application thereof. The PLA complex consists of structurally-modified Escherichia coli bacteriophage virus-like particles (VLPs) and antigens displayed thereon, and nucleic acids are encapsulated inside the VLPs.

The invention discloses an escherichia coli bacteriophage GXEC2-19, which is an escherichia coli bacteriophage GXEC2-19, the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC (China Center for Type Culture Collection) NO: M 20242555, and the preservation number of the escherichia coli bacteriophage GXEC2-19 is CCTCC NO: M 20242555. The invention also discloses an application of the coliphage GXEC2-19 in preparation of drugs for preventing and treating avian pathogenic coliphage infection diseases. The escherichia coli phage GXEC2-19 Escherichia phage GXEC2-19 disclosed by the invention can be used for effectively cracking chicken-origin pathogenic escherichia coli, wherein the chicken-origin pathogenic escherichia coli comprises escherichia coli phage DC05 and another strain of chicken-origin escherichia coli; furthermore, the coliphage GXEC2-19 can continuously inhibit bacteria for a long time, is high in stability and good in safety, can be easily prepared into preparations and the like, and has good killing, preventing and controlling effects on environments, feeds and the like polluted by the coliphage.

The application belongs to the technical field of biotechnology, and discloses a traditional Chinese medicine compound preparation containing an Escherichia coli bacteriophage DCP514 and application. The Escherichia coli bacteriophage DCP514 has a preservation number of CCTCC NO: M 2024321, can efficiently kill pathogenic variants of Escherichia coli in a poultry breeding environment, has the characteristics of strong lyticity, good temperature tolerance, environmental friendliness, and the like, and has the advantages of safety, no residue, and no side effect. The bacteriophage can be used alone or in combination with a traditional Chinese medicine extract to enhance the bacteriostatic effect, and has a good application prospect in the biological control of Escherichia coli.

Provided are a phage and a use thereof in preparing a biological formulation for inhibiting drug-resistant bacteria, relating to the field of biomedicine. An Escherichia coli phage Phage vB_EcoM_GZMU_E1004 is isolated from a mixture of lake water and sewage. The phage is deposited under the accession number GDMCC No: 64729-B1, and has the function of significantly inhibiting Escherichia coli. In addition, the combined use of the phage and allicin can further enhance the antibacterial effect against Escherichia coli. The obtained phage can reduce the use of antibiotics, enrich the natural phage resources of drug-resistant Escherichia coli, and provide an important foundation and basis for the phage treatment of drug-resistant Escherichia coli.

The invention provides a bovine-derived Escherichia coli bacteriophage, which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 2025205. The bovine-derived escherichia coli bacteriophage can survive in an environment with the pH value of 3.0-12.0, has good titer stability at the temperature of 4-50 DEG C, has good pH and temperature tolerance, and is suitable for preparing drugs and disinfectants for inhibiting bovine-derived escherichia coli.

The invention discloses a drug-resistant Escherichia coli bacteriophage with efficient cross-species lysis capability and application of the drug-resistant Escherichia coli bacteriophage, the drug-resistant Escherichia coli bacteriophage is named as Escherichia coli bacteriophage PE-48, and the preservation number of the drug-resistant Escherichia coli bacteriophage is CCTCC (China Center for Type Culture Collection) NO: M 2025261. The strain not only can efficiently split pathogenic escherichia coli, but also can split salmonella, has efficient cross-species splitting capacity, and can effectively prevent and treat various symptoms caused by escherichia coli and relieve phenomena such as large-scale death and the like. The bacteriophage is separated from the natural environment, is a natural biological purification factor, and has the advantages of being green, environmentally friendly, safe, free of residues, efficient in bacteriostasis and the like. Escherichia coli and salmonella infection can be effectively prevented and treated in the chick breeding process.

A biosensor tool that uses a novel phage Qβ display technology to monitor the presence of the biological or chemical threat. The biosensor including a probe specific to the biological or chemical threat and a detectable molecule expressed on the surface of the phage Qβ and an analyte capable of binding to the probe and blocking the detectable molecule.

The application provides a cross-species lytic bacteriophage RDP-EC-20146 and an application thereof, and belongs to the technical field of biotechnology. The cross-species lytic bacteriophage is an Escherichia coli bacteriophage, the preservation number of which is CGMCC No. 45351, and the bacteriophage is preserved in the China General Microbiological Culture Collection Center on October 28, 2022. The cross-species lytic bacteriophage RDP-EC-20146 provided by the application has high lytic activity and good physical and chemical factor tolerance characteristics; the cross-species lytic bacteriophage is not affected by bacterial drug resistance, and does not have problems such as drug residues, and has high use safety; in addition, the bacteriophage RDP-EC-20146 provided by the application can all show significant bacteriostatic effects when being used in combination with low-dose 8 kinds of antibiotics, and has a good application prospect in the prevention and treatment of salmonellosis, colibacillosis, staphylococcosis and / or pseudomonas aeruginosa disease.

This invention proposes an *Escherichia coli* bacteriophage, a bacteriophage composition, its application, and a bacteriophage preparation, relating to the field of microbial technology. The *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage GaoM7-14E, with accession number CGMCC NO.46188, deposited on September 20, 2024. Another *Escherichia coli* bacteriophage is named *Escherichia coli* bacteriophage JM3e, with accession number CGMCC NO.46186, deposited on September 18, 2024. The technical solution of this invention uses bacteriophage GaoM7-14E and bacteriophage JM3e as a bacteriophage composition, which can synergistically inhibit *Escherichia coli*, thereby inhibiting pathogenic *Escherichia coli*, and thus preventing and treating *Escherichia coli* diseases.

The invention belongs to the technical field of bacteriophages, and discloses an Escherichia coli bacteriophage PD2061, a bacteriophage composition and application thereof, the preservation number of the Escherichia coli bacteriophage PD2061 is CGMCC NO.46163, the Escherichia coli bacteriophage PD2061 is preserved in China General Microbiological Culture Collection Center on August 16, 2024, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The Escherichia coli phage PD2061 not only has a high splitting rate on Escherichia coli, but also has certain splitting performance on salmonella, and has greater advantages in prevention and treatment of diseases caused by mixed infection of Escherichia coli and salmonella. The bacteriophage can be used for preparing a medicinal preparation for treating or preventing animal-derived colibacillosis and / or salmonellosis, the survival rate of poultry suffering from colibacillosis / salmonellosis or mixed infection diseases is increased, the feed utilization rate is increased, and the death and culling rate of the poultry in breeding is reduced.

The invention discloses an Escherichia coli bacteriophage, a bacteriophage composition and application thereof, the Escherichia coli bacteriophage is an Escherichia coli bacteriophage D4 or an Escherichia coli bacteriophage D10, the preservation number of the Escherichia coli bacteriophage D4 is CGMCC NO.46363, the preservation number of the Escherichia coli bacteriophage D10 is CGMCC NO.46366, and the preservation number of the The strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 2, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The bacteriophage composition comprises the escherichia coli bacteriophage and other bacteriophages. The Escherichia coli phage D4 or D10 shows excellent splitting performance on clinically separated multi-drug-resistance Escherichia coli, can be used as an active component independently or in combination with other phages, and is used for preparing environment-friendly biological bactericides, pharmaceutical preparations or disinfectants. The compound is applied to the aspects of sterilization, bacteriostasis and disinfection of multi-drug-resistant escherichia coli, treatment or prevention of infectious diseases caused by escherichia coli and the like.

The invention discloses a strain of pathogenic escherichia coli phage, which is an escherichia coli phage GXECL1-19 (escherichia coli phage GXECL1-19), and the preservation number of the escherichia coli phage is CCTCC (China Center for Type Culture Collection) NO: M 20242554; the invention also discloses an application of the pathogenic coliphage in preparation of drugs for preventing and treating coliphage infection diseases. The pathogenic Escherichia coli bacteriophage disclosed by the invention can be used for effectively cracking swine pathogenic Escherichia coli bacteriophage, wherein the swine pathogenic Escherichia coli bacteriophage comprises Escherichia coli phage GXPD-01 and another strain of swine escherichia coli; furthermore, the pathogenic Escherichia coli bacteriophage disclosed by the invention can continuously inhibit bacteria for a long time, is high in stability and good in safety, can be easily prepared into a preparation and the like, and has good killing, preventing and controlling effects on environments, feeds and the like polluted by the Escherichia coli bacteriophage.